

Pregnancy, breastfeeding, and family planning

The current ethical framework of GCP guidelines deems it unethical to perform clinical trials in pregnant women. Therefore, there is no high-level evidence data on the efficacy and safety in this patient population. On the other hand, AE is the most common general skin disease in pregnancy. AE may either (i) worsen in women with a chronic condition, or (ii) may be reactivated in patients with a past AE history or (iii) may occur in women with no AE history (atopic eruption of pregnancy, AEP). Worsening of AE is mostly reported during the second and third trimesters, while AEP typically occurs during the first trimester.¹ There are no major clinical differences between classical AE worsening and AEP. Physiological skewness of the immune system towards a Th2-dominated response during pregnancy as well as physical and psychological stress during this period may contribute to AE worsening during pregnancy. Little is known about treatment patterns during pregnancy, but patients and caregivers tend to reduce the use of topical and systemic therapies during pregnancy to avoid presumed harm to the fetus.² Consequently, undertreatment of AE during pregnancy may lead to serious QoL impairment but also to complications such as eczema herpeticum or staphylococcus aureus skin infections, and should therefore be avoided.

Pregnant women

In pregnant women with AE, we recommend TCS class II or III.	↑↑	100%  100 % Agreement (19/19) Expert Consensus
In pregnant women with AE, we suggest that TCI may preferably be used on the face and intertriginous areas and on abdominal, breast and thigh skin, where the risk of striae formation increases with excessive use of TCS.	↑	100%  100 % Agreement (19/19) Expert Consensus
In pregnant women with AE, when topical treatments are insufficient, we recommend narrow-band UVB (311 nm) or broad spectrum UVB therapy if NB-UVB is unavailable.	↑↑	100%  100 % Agreement (19/19) Expert Consensus

In pregnant women with AE, who are candidates for systemic treatment, we suggest ciclosporin.	↑	100%  (14/14) Expert Consensus
--	---	--

In pregnant women with AE, who are being treated with azathioprine and still need a systemic treatment, we suggest continuing azathioprine.	↑	100%  (14/14) Expert Consensus
azathioprine: off-label		

In pregnant women with AE, we recommend against long term use of systemic corticosteroids - as we do in all AE patients.	↓↓	100%  100 % Agreement
In pregnant women with AE, we suggest prednisolone only as short term rescue therapy for acute flares.	↑	(16/16) Expert Consensus

In pregnant women with AE, we recommend against the use of abrocitinib, baricitinib, upadacitinib, methotrexate and mycophenolate.	↓↓	100%  (15/15) Expert Consensus
---	----	--

In pregnant women with AE, we cannot make a recommendation regarding the use of dupilumab, lebrikizumab and tralokinumab during pregnancy due to the current lack of clinical data.	0	100% 100 % Agreement (18/18) Expert Consensus
--	---	---

First line treatments

Emollients. Basic emollient therapy is key in the treatment of AE also during pregnancy and must be proposed to pregnant women with AE as a basic daily therapy. There is no firm evidence on which emollient should be used, but using one with a high lipid content and as few potentially harmful agents as possible is recommended. Using emollients in a wet wrap technique is encouraged.³

TCS. Reactive or proactive use of TCS class II or III is recommended. A Cochrane systematic review updated in 2015 including 14 studies (5 cohort and 9 case-control studies) with 1,601,515 study subjects has examined the risk of TCS use in pregnancy. Overall, it has been deemed safe, with no causal associations between maternal exposure to TCS of all potencies and pregnancy outcomes including mode of delivery, congenital abnormalities, preterm delivery, foetal death, and low Apgar score, although the use of very potent topical corticosteroids may be associated with low birthweight.⁴ Proactive, twice weekly TCS application as maintenance therapy is regarded as safe, but caution is recommended when using potent TCS over large body surface areas, or sensitive areas as breast and thigh skin, on a more regular basis. Some experts suggest that class IV may be used as rescue therapy, or over longer periods on limited skin areas, but this is controversial. Fluticasone propionate should be avoided as it is the only TCS that is known not to be metabolized by the placenta.¹ There is experimental data that there is zero degradation of Fluticasone propionate at the placental barrier, whereas the degradation of hydrocortisone is high and the degradation of betamethasone is low.^{5,6} Therefore, we specifically recommend to not use the fluticasone propionate in pregnant women.¹

TCI. Reactive and proactive use of TCI may be preferable on the face and intertriginous areas, and on abdominal, breast and thigh skin, where the risk of striae formation increases with excessive use of TCS.

Antiseptics. Antiseptics, except triclosan, may be used by pregnant women if clinically needed to prevent recurring skin infections, but are not recommended as a general routine measure.

UV phototherapy. Therapy with narrow-band UVB (311 nm) and broad-spectrum UVB does not impose a risk to the fetus in pregnant woman. However, oral psoralen should not be used preconceptionally (3 months) or in pregnant women.

Second and third line treatments

Second and third line treatments are recommended in pregnant women with AE who are inadequately controlled with TCS class II or III.

Systemic corticosteroids should not be used in the long-term in AE in general and even more so not during pregnancy, as it is associated with an increased risk of fetal complications, including gestational

diabetes.⁴ Only short courses of prednisolone (maximum 0.5 mg/kg/day) may be used with strict indication.

Ciclosporin may be used off-label in severe uncontrolled AE during pregnancy if topical anti-inflammatory treatment alone or in combination with UV treatment fails, and there is a clear need for better long-term disease control. However, extra attention should be given to the renal function and blood pressure of the mother. There is no evidence of teratogenicity. Ciclosporin crosses the placenta⁷ and should not be used during pregnancy, unless the potential benefit to the mother justifies the potential risk to the foetus.

AZA may be used off-label in pregnant women with severe uncontrolled AE, who are already receiving this treatment at the time of conception. There is no evidence for teratogenicity from studies with patients with inflammatory bowel diseases. Closely consulting an experienced obstetrician when prescribing this drug is strongly recommended.¹

MTX and mycophenolate mofetil are teratogenic and therefore strictly contra-indicated during pregnancy.

We cannot recommend any of the novel systemic medications, as there is currently no clinical data available to inform about any potential drug-associated risks. On the other hand, pre-clinical data does not indicate that there would be a teratogenic potential of dupilumab, lebrikizumab or tralokinumab if given during pregnancy.

Some physicians have used dupilumab during pregnancy, but experience, evidence, and data remains limited.⁸⁻¹⁴

Abrocitinib, baricitinib and upadacitinib are contraindicated during pregnancy according to label. There is no clinical data but single case reports supporting its safety in pregnant women, but teratogenic effects have been described for both molecules in animal models.

Antihistamines are of limited efficacy in AE (see chapter antipruritic treatment). In case of need, loratadine should preferentially be used because of the broad experience with this drug in pregnant women.

Due to lack of experience with crisaborole during pregnancy, this drug should not be used preconceptionally, in pregnancy or during lactation.

Specific consideration for breastfeeding women

In breastfeeding women with AE, we recommend TCS II or III.	↑↑	 >75% (14/15) Expert Consensus
In breastfeeding women with AE, we suggest prednisolone only as short-term rescue therapy for acute flares.	↑	

In breastfeeding women with AE, we suggest against abrocitinib, baricitinib, upadacitinib, azathioprine, ciclosporin and methotrexate.	↓	
In breastfeeding women with AE, we cannot make a recommendation regarding the use of dupilumab, lebrikizumab and tralokinumab due to the current lack of clinical data.	0	100%  100 % Agreement (18/18) Expert Consensus

TCS and TCI: No studies have examined the safety of TCS and TCI use during lactation but no harmful effect is suspected. Nevertheless, it is recommended to apply the topical treatment in the nipple region immediately after nursing the child, to allow the drug to be absorbed into the skin before the next feeding.¹

Systemic corticosteroids: Treatment with a short course of a systemic corticosteroids during lactation is safe, since <0.1% of the mother's ingested dosage is secreted into breastmilk.

With regard to biologics (dupilumab, lebrikizumab, tralokinumab), we are currently unable to make a recommendation for or against their use in breastfeeding mothers due to a lack of clinical data. However, there are indications that the concentration of biologics in general (not just IL4 and IL13 inhibitors) appears to be low in breast milk.¹⁵

MTX, AZA, ciclosporin, and JAK inhibitors are secreted in breastmilk and may induce immunosuppression in the neonate. MTX, AZA, ciclosporin, and JAK inhibitors are generally not recommended for lactating mothers.¹

Family planning

In parents with AE planning to have a child, we recommend TCS II or III or TCI.	↑↑	100%  100 % Agreement (22/22) Expert Consensus
In women with AE planning to have a child, we recommend stopping methotrexate at least 3 months before conception.*	↑↑	>75% 

In men with AE planning to have a child, we **recommend** stopping methotrexate 3 months before conception.*



(13/14)
Expert Consensus

*EMA recommends 6 months as a means of precaution, the practice of the guideline group differs from this.

Preconception recommendations for women

TCS and TCI: Although the literature on this subject is very sparse, topical AE therapies in women wishing to conceive can be used without concern.

MTX: Local labels in different countries suggest a contraindication range spanning from 1 month to 6 months before conception. European Medicines Agency (EMA) recommends 6 months as a means of precaution. The practice of the guideline group differs from this and we recommend stopping methotrexate 3 months before conception.

Preconception recommendations for men

TCS and TCI: Although the literature on this subject is very sparse, topical AE therapies in men wishing to father a child can be used without concern.

Ciclosporin may be used in the treatment of AE in men at the time of conception, as there is no evidence for harm or decreased fertility.

MTX: Following the European S3-guideline on systemic treatment of psoriasis vulgaris a 3-month MTX pause prior to conception is recommended. However, (inadvertent) exposure beyond this time does not justify termination of pregnancy, because there is no evidence of male teratogenicity.¹

AZA and JAKi: there is no contraindication for the use of AZA and JAKi in men wishing to father a child.

Dupi, Tralo, Lebri: There is currently no evidence that men need to abstain from fathering a child while on therapy. Further data is awaited to clearly demonstrate evidence of no harm.

References

1. Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. *J Eur Acad Dermatol Venereol*. Sep 2019;33(9):1644-1659. doi:10.1111/jdv.15709
2. Hamann CR, Egeberg A, Wollenberg A, Gislason G, Skov L, Thyssen JP. Pregnancy complications, treatment characteristics and birth outcomes in women with atopic dermatitis in Denmark. *J Eur Acad Dermatol Venereol*. Mar 2019;33(3):577-587. doi:10.1111/jdv.15256
3. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. *J Eur Acad Dermatol Venereol*. May 2018;32(5):657-682. doi:10.1111/jdv.14891
4. Chi CC, Wang SH, Wojnarowska F, Kirtschig G, Davies E, Bennett C. Safety of topical corticosteroids in pregnancy. *Cochrane Database Syst Rev*. Oct 26 2015;(10):Cd007346. doi:10.1002/14651858.CD007346.pub3
5. Chi CC, Kirtschig G, Aberer W, et al. Evidence-based (S3) guideline on topical corticosteroids in pregnancy. *Br J Dermatol*. Nov 2011;165(5):943-52. doi:10.1111/j.1365-2133.2011.10513.x
6. Murphy VE, Fittock RJ, Zarzycki PK, Delahunty MM, Smith R, Clifton VL. Metabolism of synthetic steroids by the human placenta. *Placenta*. Jan 2007;28(1):39-46. doi:10.1016/j.placenta.2005.12.010
7. Agency EM. Neoral Soft Gelatin Capsules - Summary of Product Characteristics (SmPC) - (emc). In).
8. Avallone G, Cavallo F, Tancredi A, et al. Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate-to-severe atopic dermatitis: A nationwide retrospective cohort study. *J Eur Acad Dermatol Venereol*. Sep 2024;38(9):1799-1808. doi:10.1111/jdv.19794
9. Bosma AL, Gerbens LAA, Middelkamp-Hup MA, Spuls PI. Paternal and maternal use of dupilumab in patients with atopic dermatitis: a case series. *Clin Exp Dermatol*. Aug 2021;46(6):1089-1092. doi:10.1111/ced.14725
10. Khamisy-Farah R, Damiani G, Kong JD, Wu JH, Bragazzi NL. Safety profile of Dupilumab during pregnancy: a data mining and disproportionality analysis of over 37,000 reports from the WHO individual case safety reporting database (VigiBase™). *Eur Rev Med Pharmacol Sci*. Sep 2021;25(17):5448-5451. doi:10.26355/eurrev_202109_26652
11. Heilskov S, Deleuran MS, Vestergaard C. Immunosuppressive and Immunomodulating Therapy for Atopic Dermatitis in Pregnancy: An Appraisal of the Literature. *Dermatol Ther (Heidelb)*. Dec 2020;10(6):1215-1228. doi:10.1007/s13555-020-00457-w
12. Drljevic-Nielsen A, Heilskov S, Deleuran MS, Vestergaard C. Immunosuppressive and immunomodulating therapy for atopic dermatitis in pregnancy: an appraisal of the literature. *Ital J Dermatol Venerol*. Feb 2024;159(1):23-33. doi:10.23736/s2784-8671.23.07692-2
13. Deleuran M, Dézfoulian B, Elberling J, et al. Systemic anti-inflammatory treatment of atopic dermatitis during conception, pregnancy and breastfeeding: Interdisciplinary expert consensus in Northern Europe. *J Eur Acad Dermatol Venereol*. Jan 2024;38(1):31-41. doi:10.1111/jdv.19512
14. Akuffo-Addo E, Nicholas MN, Lansang P. Reported Pregnancy Outcomes in Women With Severe Atopic Dermatitis Treated With Dupilumab: A Systematic Review. *Journal of cutaneous medicine and surgery*. Mar-Apr 2023;27(2):177-178. doi:10.1177/12034754231152223
15. Matro R, Martin CF, Wolf D, Shah SA, Mahadevan U. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development. *Gastroenterology*. Sep 2018;155(3):696-704. doi:10.1053/j.gastro.2018.05.040